Volume 7, Issue 2 (2021)                   IEM 2021, 7(2): 121-128 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tabanejad Z, Darvish S, Borjian Boroujeni Z, Asadi S S, Mesri M, Raiesi O, et al . Seroepidemiological Study of Novel Coronavirus Disease (COVID-19) in Tehran, Iran. IEM 2021; 7 (2) :121-128
URL: http://iem.modares.ac.ir/article-4-51006-en.html
1- Nursing Care Research Center, Iran University of Medical Sciences, Tehran, IR. Iran.
2- Department of Medical Laboratory Sciences, Faculty of Medicine, Babol University of Medical Sciences, Babol, IR. Iran.
3- Department of Medical Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR. Iran.
4- Department of Parasitology, School of Allied Medical Sciences. Ilam University of Medical Sciences, Ilam, Iran.
5- Department of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, College of Health Sciences, Bayero University, PMB 3011, Kano-Nigeria
6- Department of Medical Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR. Iran. , mahdizareei53@yahoo.com
Abstract:   (1870 Views)
Backgrounds: A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread to all countries of the world, including Iran. Although anti-SARS-CoV-2 antibodies may be identified in patients using immunological methods with sufficient sensitivity and specificity, the conclusive diagnosis of the disease is made using the molecular RT-PCR method. A population-based seroepidemiological survey was conducted to quantify the proportion of the exposed population with SARS-CoV-2 antibodies and evaluate whether the antibodies are a marker of total or partial immunity compared to the population that remains susceptible to the virus.
Material & Methods: This cross-sectional study was conducted to investigate the seroprevalence of COVID-19 in Valiasr, Sajad, and Ghaem hospitals in Tehran, the capital of Iran, from April to the end of October 2020. Clotted and heparinized blood specimens (2mL) were collected from the patients. The serum and plasma were separated and stored at −80 °C until use. Anti-SARS-CoV-2 IgG and IgM antibodies were examined in the serum samples of 1375 in-patients admitted to the hospitals using ELISA kits. The obtained data were analyzed using SPSS software Ver.22.0 by employing statistical tests such as Chi-square and Fisher’s exact tests. A p-value <.05 was considered as significant.
Findings: In total, 1375 participants were enrolled in this study, and SARS‐CoV‐2 antibodies were detected in 291 patients using IgM‐IgG antibody assay. Among the seropositive patients studied, 187 were male (64.3%), and 104 were female (35.7%) (p<.05). The mean age of the patients was 49±8.4 years; the majority of whom (27%) were in the age group of 31-40 years. Also, the lowest frequency of infected cases was related to the age group of 1-10 years (p <.05). The seroprevalence of SARS‐CoV‐2 IgM or IgG antibodies was determined to be 21.2%. Diabetes mellitus was the most common underlying disease among SARS‐CoV‐2 patients [p=.05; Odd Ratio=1.61(0.90-2.91)].
Conclusion: The use of conventional serological assays, such as the enzyme-linked immunoassay (ELISA), for detecting specific IgM and IgG antibodies in SARS‐CoV‐2 patients has a high-throughput advantage while minimizing false-negative results obtained using the RT-PCR method. In this study, the seroprevalence of SARS-CoV-2 antibodies was determined to be 21%. Control of diabetes, among other influential factors, plays an important role in the management and control of COVID-19.
Full-Text [PDF 633 kb]   (481 Downloads)    
Article Type: Original Research | Subject: Virology
Received: 2021/03/17 | Accepted: 2021/03/30 | Published: 2021/05/20

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.